How effective are topical calcineurin inhibitors for cutaneous lupus?

These medicines reduce local immune activity rather than removing the underlying tendency toward lupus inflammation. A dermatologist may consider them for delicate areas such as the face, eyelids or skin folds, where repeated topical steroid use can cause thinning. They are generally more useful for active, superficial inflammation than for established scarring or texture change. Cutaneous lupus can include different patterns, so a treatment that suits one lesion may not suit another. Improvement is assessed by less redness, scaling, tenderness or new activity, while existing pigment change or scars may remain.

Use the prescribed amount and schedule on clean, dry skin, and avoid covering the area unless your clinician specifically advises it. Mild warmth or stinging after application can occur, especially on inflamed skin; tell your prescriber if it is persistent or severe. Protect affected skin from ultraviolet exposure with shade, clothing and the sunscreen plan recommended for you, because light can aggravate cutaneous lupus. Do not stop other lupus medicines or replace them with a cream without medical guidance. Take photographs in similar lighting so changes can be discussed at review.

Arrange a dermatology review if lesions are spreading, becoming painful, ulcerated or thickened, or if hair loss or scarring is developing. Seek prompt medical advice for new mouth or nose sores, unusual sensitivity to sunlight, joint symptoms, fever, chest discomfort or marked fatigue, because these may need assessment beyond the skin. Contact the prescriber quickly if treated skin develops marked swelling, blistering, pus or a rapidly worsening rash.

Ask which cutaneous lupus pattern is being treated, what improvement should look like, how long to continue before reassessment, and whether a biopsy or additional lupus evaluation is needed. Discuss sun protection, steroid-sparing use on sensitive sites, and what to do if burning or a flare occurs.